Finally, one study qualitatively evaluated the PSMA-targeting radiopharmaceutical uptake of metastatic lesions to assess if they were suitable for PSMA-targeted radioligand therapy (RLT) using the “prostate cancer molecular imaging standardised evaluation” (PROMISE) as a benchmark to determine which patients could benefit from this treatment [24,26]. The gene discussed is FOLH1; the disease is prostate carcinoma.